PuSH - Publication Server of Helmholtz Zentrum München: Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Straube, C.* ; Scherb, H. ; Gempt, J.* ; Bette, S.* ; Zimmer, C.* ; Schmidt-Graf, F.* ; Schlegel, J.* ; Meyer, B.* ; Combs, S.E.

Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience.

Radiat. Oncol. 12:77 (2017)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

BACKGROUND: Glioblastoma is usually diagnosed around the age of 60-70 years. Patients older than 65 years are frequently described as "elderly". Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analysed the outcome of elderly glioblastoma patients treated at our facility. METHODS: We performed a retrospective analysis of 62 consecutive patients older than 65 years treated for a primary glioblastoma at our facility from 2009 to 2015. RESULTS: Median age was 69.6 years (range 65.1-85.6 years); median OS of the entire cohort was 10.9 months. ECOG, MGMT and extent of resection but not age and the time from surgery to radiotherapy were associated with longer survival. Patients treated with adjuvant chemotherapy had a significantly longer survival (20.5 vs. 7.8 months). Furthermore, salvage therapies were associated with significant improved survival when compared to Best Supportive Care (22.3 vs. 8.8 months). CONCLUSION: Also elderly patients are likely to benefit from an aggressive treatment after primary diagnosis of glioblastoma.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

2.568

1.150